During the ongoing trial of the "Dok-1 Max" case, S.K., the former head of the Agency for the Development of the Pharmaceutical Network, requested the opening of a criminal case against his colleague, Ulugbek Egamov, Daryo's correspondent reports.
S.K., who stands as a defendant in the "Dok-1 Max" case, leveled serious accusations against Ulugbek Egamov, the current head of the agency. As per the indicted former leader, he became aware of Egamov's actions during the initial investigation of the case, which has led to his present legal predicament.
"After you came to the office, all the activities in the agency started. I found out about it during the investigation, until now I was blind and didn't know. I thought it was an upgrade and that it was working well. But because of you, I am sitting here now.," addressing Egamov in court, S.K. declared.
The core of the accusations revolves around the removal of the Indian drug Curarax from inspection. S.K. claimed that he was tasked with this action during the investigation, allegedly on behalf of Ulugbek Egamov.
During the proceedings, S.K. confronted Egamov, who was called as a witness, asking if he had contacted him regarding the removal of the Curarax drug. Egamov denied any such contact. However, S.K. pressed further, inquiring about the distribution of the $33,000 bribe associated with the removal of the drug. Egamov stated that he did not see any of the money.
"I have been sitting here for 11 months because you are dirty. When you leave the courthouse, look at the eyes of my family members," expressing his frustration, S.K. noted.
The judge objected to S.K.'s characterization of Egamov, reminding him of his own responsibility and urging him not to provoke the court. Unperturbed, S.K. reiterated his accusations, prompting the judge to caution him against further actions that could lead to repercussions.
Four other former officials in the court supported S.K.'s claims, alleging that since Egamov joined the agency, there was a notable increase in directives to manipulate drug inspections. All defendants, including S.K., insisted that a criminal case should be opened against Ulugbek Egamov.
In previous court sessions, an Indian businessman admitted to paying $33,000 to prevent an inspection of his company and obtain approval for the drug "Dok-1 Max" syrup, which did not meet the required standards for Uzbekistan. S.K. further asserted that Egamov was a recipient of a share of this money, a revelation that emerged during the investigation and has yet to be fully unraveled. The courtroom saga continues as the "Dok-1 Max" case unfolds, revealing a web of corruption and intrigue within the pharmaceutical agency.
Follow Daryo's official Instagram and Twitter pages to keep current on world news.
Comments (0)